Deep Track Capital, LP Protagonist Therapeutics, Inc Transaction History
Deep Track Capital, LP
- $2.86 Billion
- Q1 2025
A detailed history of Deep Track Capital, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Deep Track Capital, LP holds 3,000,000 shares of PTGX stock, worth $133 Million. This represents 5.07% of its overall portfolio holdings.
Number of Shares
3,000,000
Previous 1,000,000
200.0%
Holding current value
$133 Million
Previous $38.6 Million
275.85%
% of portfolio
5.07%
Previous 1.7%
Shares
5 transactions
Others Institutions Holding PTGX
# of Institutions
293Shares Held
60.7MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$270 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$255 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$253 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$189 Million0.0% of portfolio
-
State Street Corp Boston, MA2.71MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.17B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...